tiprankstipranks
Advertisement
Advertisement

TSE:EPRX Stock Latest News

Eupraxia Pharmaceuticals Posts Strong Histologic Gains in Mid-Stage EoE Trial for EP-104GI
Company AnnouncementsEupraxia Pharmaceuticals Posts Strong Histologic Gains in Mid-Stage EoE Trial for EP-104GI
1d ago
6K
EPRX
Eupraxia Pharmaceuticals Highlights Strong EP-104GI EoE Data From RESOLVE Trial at DDW
PremiumCompany Announcements
Eupraxia Pharmaceuticals Highlights Strong EP-104GI EoE Data From RESOLVE Trial at DDW
2d ago
6K
EPRX
Buy Rating Backed by Favorable Safety and Promising Efficacy Data for EP-104GI in Eosinophilic Esophagitis
PremiumRatings
Buy Rating Backed by Favorable Safety and Promising Efficacy Data for EP-104GI in Eosinophilic Esophagitis
3d ago
EPRX
Eupraxia Pharmaceuticals Names New Chief Medical Officer to Steer Late-Stage Pipeline
PremiumCompany Announcements
Eupraxia Pharmaceuticals Names New Chief Medical Officer to Steer Late-Stage Pipeline
6d ago
6K
EPRX
Eupraxia Pharmaceuticals names Dr. Jeymi Tambiah as Chief Medical Officer
PremiumThe Fly
Eupraxia Pharmaceuticals names Dr. Jeymi Tambiah as Chief Medical Officer
6d ago
EPRX
Eupraxia Pharmaceuticals to Showcase EP-104GI Data at Digestive Disease Week 2026
PremiumCompany AnnouncementsEupraxia Pharmaceuticals to Showcase EP-104GI Data at Digestive Disease Week 2026
15d ago
6K
EPRX
Eupraxia Pharmaceuticals: Strong EP-104GI Clinical Durability and Dose-Response Support Buy Rating and Favorable Risk-Reward
Premium
Ratings
Eupraxia Pharmaceuticals: Strong EP-104GI Clinical Durability and Dose-Response Support Buy Rating and Favorable Risk-Reward
15d ago
EPRX
Eupraxia Posts Strong 36-Week EoE Data From Highest-Dose Cohort in RESOLVE Trial
Premium
Company Announcements
Eupraxia Posts Strong 36-Week EoE Data From Highest-Dose Cohort in RESOLVE Trial
16d ago
6K
EPRX
Encouraging EP-104GI EoE Data and Strong Cash Runway Underpin Buy Rating on Eupraxia
PremiumRatings
Encouraging EP-104GI EoE Data and Strong Cash Runway Underpin Buy Rating on Eupraxia
16d ago
EPRX
Compelling EP‑104GI Eosinophilic Esophagitis Data and Safety Profile Underpin Buy Rating and Attractive Risk‑Reward Ahead of Phase IIb Catalysts
PremiumRatings
Compelling EP‑104GI Eosinophilic Esophagitis Data and Safety Profile Underpin Buy Rating and Attractive Risk‑Reward Ahead of Phase IIb Catalysts
16d ago
EPRX
Eupraxia reports 9-month tissue symptom data from Phase 1b/2a Resolve trial
PremiumThe Fly
Eupraxia reports 9-month tissue symptom data from Phase 1b/2a Resolve trial
16d ago
EPRX
Eupraxia Pharmaceuticals to Highlight Drug-Delivery Pipeline at April Investor Conferences
PremiumCompany Announcements
Eupraxia Pharmaceuticals to Highlight Drug-Delivery Pipeline at April Investor Conferences
23d ago
EPRX
Eupraxia Pharmaceuticals: Underdiagnosed EoE Market Expands Upside, Supporting Buy Rating on EPRX
PremiumRatingsEupraxia Pharmaceuticals: Underdiagnosed EoE Market Expands Upside, Supporting Buy Rating on EPRX
1M ago
EPRX
Eupraxia Pharmaceuticals initiated with an Outperform at William Blair
Premium
The Fly
Eupraxia Pharmaceuticals initiated with an Outperform at William Blair
2M ago
EPRX
Eupraxia: Differentiated Once-Yearly EoE Therapy and Platform Expansion Support Buy Rating
Premium
Ratings
Eupraxia: Differentiated Once-Yearly EoE Therapy and Platform Expansion Support Buy Rating
2M ago
EPRX
Eupraxia Pharmaceuticals: Durable EP-104GI Data and Upcoming Catalysts Support Buy Rating
PremiumRatings
Eupraxia Pharmaceuticals: Durable EP-104GI Data and Upcoming Catalysts Support Buy Rating
2M ago
EPRX
Eupraxia Pharmaceuticals Posts Strong Six-Month EoE Data for EP-104GI as RESOLVE Trial Advances
PremiumCompany Announcements
Eupraxia Pharmaceuticals Posts Strong Six-Month EoE Data for EP-104GI as RESOLVE Trial Advances
2M ago
6K
EPRX
Eupraxia Pharmaceuticals’ esophagitis candidate shows symptom decrease
PremiumThe Fly
Eupraxia Pharmaceuticals’ esophagitis candidate shows symptom decrease
2M ago
EPRX
Eupraxia price target lowered to $11 from $12 at H.C. Wainwright
PremiumThe Fly
Eupraxia price target lowered to $11 from $12 at H.C. Wainwright
2M ago
EPRX
Buy Rating on Eupraxia Pharmaceuticals Driven by EP-104GI’s Differentiated Technology and Favorable Risk‑Reward Profile
PremiumRatingsBuy Rating on Eupraxia Pharmaceuticals Driven by EP-104GI’s Differentiated Technology and Favorable Risk‑Reward Profile
2M ago
EPRX
Eupraxia (EPRX): Robust Cash Runway and Promising EP-104GI GI Pipeline Create Attractive Risk‑Reward and Support Buy Rating
Premium
Ratings
Eupraxia (EPRX): Robust Cash Runway and Promising EP-104GI GI Pipeline Create Attractive Risk‑Reward and Support Buy Rating
2M ago
EPRX
Eupraxia Widens Q4 Loss but Extends Cash Runway With $63 Million Financing
Premium
Company Announcements
Eupraxia Widens Q4 Loss but Extends Cash Runway With $63 Million Financing
2M ago
EPRX

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >